Hide metadata

dc.date.accessioned2021-04-21T20:22:47Z
dc.date.available2021-04-21T20:22:47Z
dc.date.created2020-09-08T12:30:48Z
dc.date.issued2020
dc.identifier.citationHuitfeldt, Anders Sundbakk, Lene Maria Skurtveit, Svetlana Handal, Marte Nordeng, Hedvig Marie Egeland . Associations of Maternal Use of Benzodiazepines or Benzodiazepine-like Hypnotics During Pregnancy With Immediate Pregnancy Outcomes in Norway. JAMA Network Open. 2020, 3(6)
dc.identifier.urihttp://hdl.handle.net/10852/85445
dc.description.abstractImportance Understanding the safety profile of medications used in pregnancy is crucial for clinical decision-making. Few studies exist on the associations of exposure to benzodiazepines and benzodiazepine-like hypnotic drugs (z-hypnotics) in pregnancy with pregnancy outcomes. Objective To determine whether exposure to benzodiazepines or z-hypnotics in pregnancy is associated with greater risk of negative immediate pregnancy outcomes compared with nonexposure. Design, Setting, and Participants This questionnaire-based cohort study used data from the Norwegian Mother, Father and Child cohort study (MoBa), which also includes data from the Medical Birth Registry of Norway. Pregnant women were recruited from all over Norway from 1999 and 2008. The first child was born in October 1999 and the last in July 2009. This analysis included women who completed 3 questionnaires, twice during pregnancy and once 6 months after delivery. Data analyses were conducted from September to November 2019. Exposures Self-reported exposure to benzodiazepines or z-hypnotics during pregnancy, characterized in terms of any exposure, timing (ie, early, middle, or late), and duration of exposure. Main Outcomes and Measures The main outcomes were gestational age at delivery, risk of preterm delivery, birth weight, birth weight relative to gestational age and sex, risk of being small for gestational age, head circumference, Apgar score less than 7 at 5 minutes, and risk of neonatal respiratory distress. Continuous outcomes are reported using effect estimates as mean differences, and binary outcomes are reported using risk ratios. Results The MoBa study included 114 234 mother-child dyads. This analysis of MoBa data includes 82 038 singleton pregnancies among 69 434 unique women. Mean (SD) maternal age was 30.2 (4.5) years, and 37 641 pregnancies (45.9%) were in primiparous women. Exposure to benzodiazepines or z-hypnotics was reported in 679 pregnancies (0.8%). After adjusting for all measured baseline and postbaseline confounders, benzodiazepine or z-hypnotic use during pregnancy was associated with lower birth weight (mean difference, −79.3 [95% CI, −126.7 to −31.9] g), lower gestational age at birth (mean difference, −2.1 [95% CI, −3.3 to −0.9] days), and higher risk of preterm birth (risk ratio, 1.41 [95% CI, 1.03 to 1.94]). We found no significant association of exposure to benzodiazepines or z-hypnotics with the child’s birth weight relative to gestational age and sex (z score), or any of the other immediate birth outcomes. Conclusions and Relevance These findings suggest that the magnitude of the association of exposure to benzodiazepines or z-hypnotics with gestational age is not necessarily clinically significant. The absence of an association of exposure to benzodiazepines or z-hypnotics with z score for birth weight relative to gestational age and sex suggests that association of exposure to benzodiazepines or z-hypnotics with birth weight could be explained by earlier delivery rather than impaired intrauterine growth.
dc.languageEN
dc.publisherAmerican Medical Association
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleAssociations of Maternal Use of Benzodiazepines or Benzodiazepine-like Hypnotics During Pregnancy With Immediate Pregnancy Outcomes in Norway
dc.typeJournal article
dc.creator.authorHuitfeldt, Anders
dc.creator.authorSundbakk, Lene Maria
dc.creator.authorSkurtveit, Svetlana
dc.creator.authorHandal, Marte
dc.creator.authorNordeng, Hedvig Marie Egeland
cristin.unitcode185,15,23,10
cristin.unitnameGalenisk farmasi og samfunnsfarmasi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1828071
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=JAMA Network Open&rft.volume=3&rft.spage=&rft.date=2020
dc.identifier.jtitleJAMA Network Open
dc.identifier.volume3
dc.identifier.issue6
dc.identifier.doihttps://doi.org/10.1001/jamanetworkopen.2020.5860
dc.identifier.urnURN:NBN:no-88117
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2574-3805
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/85445/1/Huitfeldt_2020_Ass.pdf
dc.type.versionPublishedVersion
cristin.articleide205860
dc.relation.projectERC/639377


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International